Document:

Ex10.195 Jul Sup Ind 7.25-2022

Exhibit 10.195
EXECUTION VERSION

SUPPLEMENTAL INDENTURE
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of July 10, 2014, among Endo Netherlands B.V. (the “Guaranteeing Subsidiary”), a subsidiary of Endo Limited, a private limited company incorporated under the laws of Ireland (the “Company”), the Issuers, the other Guarantors (both, as defined in the Indenture referred to below) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”).
W I T N E S S E T H
WHEREAS, Endo Finance LLC, a Delaware limited liability company, and Endo Finco Inc., a Delaware corporation, have heretofore executed and delivered to the Trustee  an indenture, dated as of May 6, 2014, as supplemented by a supplemental indenture, dated as of May 28, 2014, among the Issuers, the Guarantors party thereto and the Trustee (as so supplemented, the “Indenture”), providing for the issuance of 7.25% Senior Notes due 2022 (the “Notes”);
WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiary shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiary shall unconditionally guarantee all of the Issuers’ Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Note Guarantee”); 
WHEREAS, this Supplemental Indenture has not resulted in a material modification of the Notes for Foreign Account Tax Compliance Act purposes; and
WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture.
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiary and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:
1.    CAPITALIZED TERMS.  Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.
2.    AGREEMENT TO GUARANTEE.  The Guaranteeing Subsidiary hereby agrees to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including but not limited to Article 10 thereof.
4.    NO RECOURSE AGAINST OTHERS.  No director, officer, employee, incorporator or stockholder of the Issuers or any Guarantor, as such, will have any liability for any obligations of the Issuers or the Guarantors under the Notes, the Indenture, this Supplemental Indenture, the Note Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation.  Each Holder of Notes by accepting a Note waives and releases all such liability.  The waiver and release are part of the consideration for issuance of the Notes.  The waiver may not be effective to waive liabilities under the federal securities laws.
5.    NEW YORK LAW TO GOVERN; WAIVER OF JURY TRIAL.  THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.  EACH OF THE ISSUERS 

Exhibit 10.195
EXECUTION VERSION

AND THE GUARANTORS CONSENTS AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY NEW YORK STATE OR U.S. FEDERAL COURT LOCATED IN THE BOROUGH OF MANHATTAN, CITY OF NEW YORK, COUNTY OF NEW YORK, STATE OF NEW YORK IN RELATION TO ANY LEGAL ACTION OR PROCEEDING (I) ARISING OUT OF, RELATING TO OR IN CONNECTION WITH THIS INDENTURE, AS SUPPLEMENTED, THE NOTES, THE GUARANTEES AND ANY RELATED DOCUMENTS AND/OR (II) ARISING UNDER ANY U.S. FEDERAL OR U.S. STATE SECURITIES LAWS IN RESPECT OF THE NOTES, THE GUARANTEES AND ANY SECURITIES ISSUED PURSUANT TO THE TERMS OF THE INDENTURE, AS SUPPLEMENTED.  EACH OF THE ISSUERS AND THE GUARANTORS WAIVES ANY OBJECTION TO PROCEEDINGS IN ANY SUCH COURTS, WHETHER ON THE GROUND OF VENUE OR ON THE GROUND THAT THE PROCEEDINGS HAVE BEEN BROUGHT IN AN INCONVENIENT FORUM.  EACH OF THE ISSUERS AND THE GUARANTORS, TO THE EXTENT ORGANIZED OUTSIDE OF THE UNITED STATES, SHALL APPOINT CT CORPORATION SYSTEM, 111 EIGHTH AVENUE, 13TH FLOOR, NEW YORK, NY 10011, AS ITS AGENT FOR SERVICE OF PROCESS IN ANY SUCH SUIT, ACTION OR PROCEEDING AND AGREES THAT SERVICE OF PROCESS UPON SAID AUTHORIZED AGENT SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON IT IN ANY SUCH SUIT, ACTION OR PROCEEDING. EACH OF THE ISSUERS AND THE GUARANTORS AGREES TO DELIVER, UPON THE EXECUTION AND DELIVERY OF THIS SUPPLEMENTAL INDENTURE, A WRITTEN ACCEPTANCE BY SUCH AGENT OF ITS APPOINTMENT AS SUCH AGENT. EACH OF THE ISSUERS AND THE GUARANTORS, TO THE EXTENT ORGANIZED OUTSIDE OF THE UNITED STATES, FURTHER AGREES TO TAKE ANY AND ALL ACTION, INCLUDING THE FILING OF ANY AND ALL SUCH DOCUMENTS AND INSTRUMENTS, AS MAY BE REASONABLY NECESSARY TO CONTINUE SUCH DESIGNATION AND APPOINTMENT OF CT CORPORATION SYSTEM IN FULL FORCE AND EFFECT FOR SO LONG AS THE INDENTURE, AS SUPPLEMENTED, REMAINS IN FORCE.  EACH OF THE ISSUERS, THE TRUSTEE AND THE GUARANTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS SUPPLEMENTAL INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY.
6.    COUNTERPARTS.  The parties may sign any number of copies of this Supplemental Indenture.  Each signed copy (which may be provided via facsimile or other electronic transmission) shall be an original, but all of them together represent the same agreement.  
7.    EFFECT OF HEADINGS.  The Section headings herein are for convenience only and shall not affect the construction hereof.
8.    THE TRUSTEE.  The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiary and the Issuers.

Exhibit 10.195
EXECUTION VERSION

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and attested, all as of the date first above written.
 
	
			
	ENDO NETHERLANDS B.V., as Guaranteeing Subsidiary

	 
	 
	 

	By:
	/s/ Blaine Davis     

	 
	Name:
	Blaine Davis 

	 
	Title:
	Managing Director A

	 
	 
	 

	By:
	/s/ Gert Jan Rietberg     

	 
	Name:
	Gert Jan Rietberg

	 
	Title:
	Managing Director B

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	ENDO FINANCE LLC 
  as an Issuer

	 
	by ENDO LUXEMBOURG FINANCE COMPANY I 
S.À R.L., its sole member

	 
	 
	 

	By:
	/s/ Andrew O'Shea                                        

	 
	Name:
	Andrew O'Shea

	 
	Title:
	B Manager

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	ENDO FINCO INC.
  as an Issuer

	 
	 
	 

	By:
	/s/ Deanna Voss                                            

	 
	Name:
	Deanna Voss

	 
	Title:
	Secretary

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	ENDO LLC 
ENDO U.S. INC. 
  each, as a Guarantor

	 
	 
	 

	By:
	/s/ Deanna Voss                                            

	 
	Name:
	Deanna Voss

	 
	Title:
	Secretary

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	ENDO HEALTH SOLUTIONS INC. 
ENDO PHARMACEUTICALS INC. 
ENDO PHARMACEUTICALS SOLUTIONS INC. 
ENDO PHARMACEUTICALS VALERA INC. 
GENERICS INTERNATIONAL (US PARENT), INC. 
GENERICS INTERNATIONAL (US MIDCO), INC.  
GENERICS INTERNATIONAL (US HOLDCO), INC. 
GENERICS INTERNATIONAL (US), INC. 
AMERICAN MEDICAL SYSTEMS HOLDINGS, INC.  
AMERICAN MEDICAL SYSTEMS, INC. 
AMS RESEARCH CORPORATION 
AMS SALES CORPORATION 
LASERSCOPE 
  each, as a Guarantor

	 
	 
	 

	By:
	/s/ Deanna Voss                                            

	 
	Name:
	Deanna Voss

	 
	Title:
	Assistant Secretary

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	GENERICS BIDCO I, LLC 
VINTAGE PHARMACEUTICALS, LLC 
GENERICS BIDCO II, LLC 
MOORES MILL PROPERTIES LLC 
WOOD PARK PROPERTIES LLC 
QUARTZ SPECIALTY PHARMACEUTICALS, LLC 
  each, as a Guarantor
  by GENERICS INTERNATIONAL (US), INC., 
  its manager

	  
	 
	 

	By:
	/s/ Deanna Voss                                            

	 
	Name:
	Deanna Voss

	 
	Title:
	Assistant Secretary

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	LEDGEMONT ROYALTY SUB LLC 
  as a Guarantor 
  by ENDO PHARMACEUTICALS SOLUTIONS INC., 
  its manager

	  
	 
	 

	By:
	/s/ Deanna Voss                                            

	 
	Name:
	Deanna Voss

	 
	Title:
	Assistant Secretary

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	ENDO LIMITED
  as a Guarantor

	 
	 
	 

	By:
	/s/ Blaine Davis     

	 
	Name:
	Blaine Davis 

	 
	Title:
	Attorney

	
			
	ENDO VENTURES LIMITED
  as a Guarantor

	 
	 
	 

	By:
	/s/ Blaine Davis     

	 
	Name:
	Blaine Davis 

	 
	Title:
	Attorney

	
			
	ENDO MANAGEMENT LIMITED
  as a Guarantor

	 
	 
	 

	By:
	/s/ Blaine Davis     

	 
	Name:
	Blaine Davis 

	 
	Title:
	Attorney

	
			
	ENDO FINANCE LIMITED
  as a Guarantor

	 
	 
	 

	By:
	/s/ Blaine Davis     

	 
	Name:
	Blaine Davis 

	 
	Title:
	Attorney

 

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	ENDO LUXEMBOURG HOLDING COMPANY S.À R.L. 
  as a Guarantor

	 
	 
	 

	By:
	/s/ Andrew O'Shea     

	 
	Name:
	Andrew O'Shea

	 
	Title:
	B Manager

	
			
	ENDO LUXEMBOURG FINANCE COMPANY I S.À R.L. 
  as a Guarantor

	 
	 
	 

	By:
	/s/ Andrew O'Shea     

	 
	Name:
	Andrew O'Shea

	 
	Title:
	B Manager

	
			
	ENDO LUXEMBOURG FINANCE COMPANY II S.À R.L. 
  as a Guarantor

	 
	 
	 

	By:
	/s/ Andrew O'Shea     

	 
	Name:
	Andrew O'Shea

	 
	Title:
	B Manager

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	PALADIN LABS CANADIAN HOLDING INC. 
  as a Guarantor

	 
	 
	 

	By:
	/s/ Mark Beaudet     

	 
	Name:
	Mark Beaudet

	 
	Title:
	President

	
			
	PALADIN LABS INC. 
  as a Guarantor

	 
	 
	 

	By:
	/s/ Mark Beaudet     

	 
	Name:
	Mark Beaudet

	 
	Title:
	President

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	ENDO VENTURES BERMUDA LIMITED, as a Guarantor 

	 
	 
	 

	By:
	/s/ Robert Rush     

	 
	Name:
	Robert Rush

	 
	Title:
	Director

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]

Exhibit 10.195
EXECUTION VERSION

	
			
	WELLS FARGO BANK, NATIONAL ASSOCIATION, 
  as Trustee

	 
	 
	 

	By:
	/s/ Martin Reed     

	 
	Name:
	Martin Reed

	 
	Title:
	Vice President

[Signature Page to 7.25% Notes due 2022 Supplemental Indenture]EX-10.1

 Exhibit 10.1 

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT 

This AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the “Amendment”) is dated effective as of July 31, 2014 (the “Effective
Date”), and amends that certain Employment Agreement, dated effective as of March 18, 2014 (the “Original Agreement”), by and between Identiv, Inc., a Delaware corporation (the “Company”), and Lawrence Midland, a
resident of California (hereinafter referred to as “Midland” or “Executive”). This Amendment and the Original Agreement are collectively referred to herein as the “Agreement.” 

For good and valuable consideration, the sufficiency and adequacy of which is hereby acknowledged, the parties amend the Original Agreement
effective as of the Effective Date, as follows: 
  

	1.	Position and Responsibilities. The second paragraph of the Agreement is hereby amended by adding at the end thereof: 

“Notwithstanding the foregoing, as and from the Effective Date, Midland shall resign his position as an executive officer of the Company
and be accordingly relieved from his obligations as President of the Company and any position he may then hold as an officer, employee or director of any of the Company’s affiliates, subsidiaries and group companies. 

 

	2.	Compensation. 

  

	 	(a)	Base Salary. Section 2(a) of the Agreement is hereby amended by adding at the end thereof: 

“Notwithstanding the foregoing, as and from the Effective Date, the Company shall pay to Midland a fixed salary at the rate of $16,666.67
per month, less applicable taxes and withholding, for 12 months as full and final base salary due and owing to Midland under the Agreement. 
  

	 	(b)	Bonus. Section 2(b) of the Agreement is hereby amended and restated to read in its entirety as follows: 

“Midland will receive a monthly payment of $4,861.11 for 12 months beginning with the month following the Effective Date, less applicable
taxes and withholding, as full settlement of the pro-rata portion of his executive bonus for 2014 to the Effective Date. In exchange for such payments, Midland waives the right to participate in the Company’s Incentive Compensation Plan for
2014 or any period subsequent thereto, and/or any other incentive compensation plan in effect for executive management of the Company from time to time. Midland acknowledges and agrees that Section 2(b) of the Original Agreement shall have no
further force or effect as of the date hereof and expressly waives any right or entitlement thereunder.” 

  
 1 

	3.	Benefits, Perquisites and Business Expenses. 

  

	 	(a)	Section 3(a) of the Agreement is hereby amended by adding at the end thereof: 

 “Subject
to Section 5 of the Agreement, as amended, the Company agrees (i) that any options to purchase shares of the Company’s common stock (“Stock Options”) that have been granted by the Company to Midland on or prior to the Termination Date
(as defined herein) and that remain unvested as of the Termination Date shall thereupon become fully vested, (ii) that all Stock Options that remain unexercised as of the Termination Date shall be exercisable for a period of two years thereafter
(but not later than the expiration of the applicable Stock Option’s original term), and (iii) that all Restricted Stock Units (RSU’s) that have been granted by the Company to Midland on or prior to the Termination Date and that remain
unvested as of the Termination Date shall thereupon become fully vested (Sections 3(a)(i-iii) together, the “Acceleration of Vesting”).” 
  

	 	(b)	Section 3(b) of the Agreement is hereby amended by adding at the end thereof: 

 “For the
avoidance of doubt, reimbursement of all reasonable business expenses, to which Midland is entitled under Section 3(b) of the Agreement will continue at the current levels in accordance with Company policy until the Termination Date and will
terminate upon the close of business on such date.” 
  

	 	(c)	Section 3(c) of the Agreement is hereby amended by adding at the end thereof: 

 “For the
avoidance of doubt, Executive’s participation in the Company’s health and welfare programs in which he currently participates will remain in effect through the Termination Date, subject to their terms and conditions. In addition, the
Company will add Midland’s spouse to the Company dental plan for the period from August 1, 2014 to the Termination Date.” 
  

	4.	Term and Termination. 

  

	 	(a)	Section 4(a) of the Agreement is hereby amended and restated to read in its entirety as follows: 

“This Agreement shall terminate on July 31, 2015 (the “Termination Date”) and thereafter shall have no further force or effect
except as provided by Section 6 of this Amendment. Sections 4(b), (d) and (e) of the Original Agreement are hereby deleted in there entirety and shall have no further force or effect.” 

 

	 	(b)	Death. Section 4(f) of the Agreement is hereby amended and restated in its entirety as follows: 

“In the event of the death of Midland prior to the payment in full of all amounts described in Section 2(a) and Section 2(b) of this
Amendment, the Company shall continue to pay to “The Midland Family Trust” such amounts and at the times provided by such Sections.” 

  
 2 

	5.	Release of Claims. As a condition of, and in consideration for the Acceleration of Vesting, Midland agrees to execute a full general release, in a form prepared by or otherwise acceptable to the Company,
releasing all claims, known or unknown, that Midland may have against the Company and its officers, directors, employees and affiliated companies, arising out of or in any way related to Midland’s employment or termination of employment with
Company (the “Release”), and the period for revocation, if any, of the Release shall have lapsed without the Release having been revoked on or before the 30th day following the Termination Date. 

 

	6.	Continuing Obligations. The parties agree that Sections 5 (Confidential Information), 6 (Non-Competition and Non-Solicitation), 8 (Notices), and 11 (Arbitration) of the Original Agreement shall survive the
Termination Date. 

  

	7.	Compliance with Section 409A. Section 7 of the Agreement is hereby amended by adding at the end thereof a new paragraph (c) to read in its entirety as follows: 

“No amount payable pursuant to this Agreement on account of the Executive’s termination of employment with the Company which
constitutes a “deferral of compensation” within the meaning of Section 409A shall be paid unless and until the Executive has incurred a “separation from service” within the meaning of Section 409A. Furthermore, if the Executive
is a “specified employee” within the meaning of Section 409A (determined using the identification methodology selected by Company from time to time, or if none, the default methodology) as of the date of the Executive’s separation
from service, no amount that constitutes a deferral of compensation which is payable on account of the Executive’s separation from service shall paid to the Executive before the date (the “Delayed Payment Date”) which is first day of
the seventh month after the date of the Executive’s separation from service or, if earlier, the date of the Executive’s death following such separation from service. All such amounts that would, but for this Section, become payable prior
to the Delayed Payment Date will be accumulated and paid in a lump sum on the Delayed Payment Date. Thereafter, any payments that remain outstanding as of the day immediately following the Delayed Payment Date shall be paid without delay over the
time period originally scheduled, in accordance with the terms of this Agreement.” 
  

	8.	Continuation of Other Terms. Except as otherwise provided by this Amendment, the terms and conditions of the Original Agreement are hereby ratified and confirmed in full. 

 

	9.	Governing Law. This Amendment shall be deemed a contract under, and for all purposes shall be governed by and construed in accordance with the laws of the state of California. 

 

	10.	Entire Agreement. The Agreement, as amended hereby, contains the entire agreement between the parties hereto with respect to the matters herein and supersedes all prior agreements and understandings, oral or
written, between the parties hereto, relating to such matters. 

  
 3 

	11.	Miscellaneous. 

  

	 	(a)	If any provision of this Amendment shall be fully or partly invalid or unenforceable, the validity and enforceability of all other provisions shall remain in effect. 

 

	 	(b)	Midland acknowledges and agrees that this Amendment may be filed by the Company with the U.S. Securities and Exchange Commission and any other regulatory body or legal authority to which the Company is subject.

  

	 	(c)	No provision of this Amendment may be amended or waived unless such amendment or waiver is authorized by the Company (including any authorized officer or committee of the Board of Directors) and signed by Midland. No
waiver by either party hereto of any breach by the other party of any condition or provision of this Amendment to be performed by such other party shall be deemed a waiver of a similar or dissimilar breach, condition or provision at the same time or
at any prior or subsequent time. 

  

	 	(d)	This Agreement may be executed in one or more counterparts, each of which when taken together shall constitute one complete document. 

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement in two counterparts on the date first above written. 

 

							
	IDENTIV, INC.	  		  	LAWRENCE MIDLAND
				
	 By:
	 	   /s/ Jason D. Hart
	  		  	   /s/ Lawrence Midland

		 	Jason D. Hart	  		  	Lawrence Midland
		 	Chief Executive Officer	  		  	

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]